AU2024219731A1 — Use of sublingual Dexmedetomidine for the treatment of agitation
Assigned to Bioxcel Therapeutics Inc · Expires 2024-10-10 · 2y expired
What this patent protects
Jse of Sublingual Dexmedetomidine for the treatment of Agitation The present invention discloses a method of treating agitation or the signs of agitation in a 5 subject comprising the sublingual administration of an effective amount of an a[pha-2 adrenergic agonist, more parti…
USPTO Abstract
Jse of Sublingual Dexmedetomidine for the treatment of Agitation The present invention discloses a method of treating agitation or the signs of agitation in a 5 subject comprising the sublingual administration of an effective amount of an a[pha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly 10 Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation orthe signs of agitation in a subject, but does not cause significant sedation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.